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Abstract
Background: Reactivation of p53 by either gene transfer or pharmacologic approaches may compensate for loss of 
p19Arf or excess mdm2 expression, common events in melanoma and glioma. In our previous work, we constructed 
the pCLPG retroviral vector where transgene expression is controlled by p53 through a p53-responsive promoter. The 
use of this vector to introduce p19Arf into tumor cells that harbor p53wt should yield viral expression of p19Arf which, 
in turn, would activate the endogenous p53 and result in enhanced vector expression and tumor suppression. Since 
nutlin-3 can activate p53 by blocking its interaction with mdm2, we explored the possibility that the combination of 
p19Arf gene transfer and nutlin-3 drug treatment may provide an additive benefit in stimulating p53 function.
Methods: B16 (mouse melanoma) and C6 (rat glioma) cell lines, which harbor p53wt, were transduced with pCLPGp19 
and these were additionally treated with nutlin-3 or the DNA damaging agent, doxorubicin. Viral expression was 
confirmed by Western, Northern and immunofluorescence assays. p53 function was assessed by reporter gene activity 
provided by a p53-responsive construct. Alterations in proliferation and viability were measured by colony formation, 
growth curve, cell cycle and MTT assays. In an animal model, B16 cells were treated with the pCLPGp19 virus and/or 
drugs before subcutaneous injection in C57BL/6 mice, observation of tumor progression and histopathologic analyses.
Results: Here we show that the functional activation of endogenous p53wt in B16 was particularly challenging, but 
accomplished when combined gene transfer and drug treatments were applied, resulting in increased transactivation 
by p53, marked cell cycle alteration and reduced viability in culture. In an animal model, B16 cells treated with both 
p19Arf and nutlin-3 yielded increased necrosis and decreased BrdU marking. In comparison, C6 cells were quite 
susceptible to either treatment, yet p53 was further activated by the combination of p19Arf and nutlin-3.
Conclusions: To the best of our knowledge, this is the first study to apply both p19Arf and nutlin-3 for the stimulation 
of p53 activity. These results support the notion that a p53 responsive vector may prove to be an interesting gene 
transfer tool, especially when combined with p53-activating agents, for the treatment of tumors that retain wild-type 
p53.
Background
For those tumors that retain wild type p53 (p53 wt),
maintenance of the tumor phenotype depends on its abil-
ity to hold p53 wt in an inactive form even long after the
initial transformation events [1-4]. These studies showed
that reactivation of p53 impeded tumor growth, rekin-
dling interest in this treatment approach. However, the
induction of p53 function may meet with significant bar-
riers, such as loss of p19Arf (p14ARF in humans) or over-
expression of mdm2 (HDM2 in humans).
For melanomas, p53 wt is present in 90% of cases, over-
expression of HDM2 is found in 56% cases [5,6] and loss
of the CDKN2A locus (where p14ARF resides) occurs in
some 50% of primary melanomas [7]. In comparison, pri-
mary human gliomas retain p53 wt in 70% of cases [8],
the loss of p14ARF appears to be a reciprocal event [9]
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and 50% of cases over-express HDM2 [10]. These find-
ings indicate that maintenance of inactivated p53 wt in
melanomas and gliomas is directly associated with
p14ARF/HDM2 status and that this axis may serve as a
therapeutic target [11].
Re-activation of p53 may be achieved by gene transfer
or pharmacologic approaches. Gene transfer studies have
shown that introduction of p14ARF can activate p53 [12-
14]. Drug treatment with nutlin-3, a small molecule com-
pound that specifically blocks the interaction of mdm2/
HDM2 with p53, results in the protection of p53 from
proteolytic degradation [15,16]. However, not all tumor
cells with p53wt are sensitive to nutlin-3 treatment, an
effect thought to be related to mdmx/HDMX activity
[17,18]. To the best of our knowledge, there are no
reports in the literature where p19Arf gene transfer was
combined with nutlin-3 drug treatment. Since p19Arf has
been shown to interact with and inhibit mdmx [19,20],
this may provide an additional mechanism for establish-
ing nutlin-3 sensitivity.
We present here the use of a p53-responsive retroviral
vector, pCLPG, for the transfer of the p19Arf cDNA. We
have shown previously that pCLPG provided p53-specific
e x p r e s s i o n  t h a t  w a s ,  i n  s o m e  c e l l s ,  s t r o n g e r  t h a n  t h e
expression level of the parental, non-modified vector,
pCL [21]. When the pCLPG vector was employed for
transfer of the p53 cDNA, a positive feedback regulatory
mechanism was established that both drove vector
expression and also blocked tumor cell proliferation [22].
Here the pCLPG vector was used to introduce the p19Arf
cDNA in cells harboring endogenous p53 wt in order to
explore the interplay between the vector, the transgene
and cellular p53.
The pCLPGp19 virus was used to treat cell lines that
carry wild type p53, B16 (mouse melanoma, p19Arf-null)
and C6 (rat glioma, p19Arf-null). Since p19Arf can work
in conjunction with the p53 pathway, we proposed that
introduction of exogenous p19Arf may functionally acti-
vate endogenous p53, impacting both vector expression
and tumor cell proliferation. These gene transfer experi-
ments were performed with or without additional drug
treatment (doxorubicin, nutlin-3) to determine if com-
bined genetic and pharmacologic therapies could over-
come the barriers to p53 function in these cells.
Methods
Construction of vectors
The construction of the pCLPG vector containing eGFP
has been described previously [21,22]. In these studies,
we showed that expression from the pCLPG-ΔU3 con-
struct offered the strongest response to p53 and was cho-
sen for further study, though it is referred to here simply
as pCLPG. The p19Arf cDNA (kindly provided by
Charles Sherr, St. Jude's Children's Hospital, Memphis,
TN) was first subcloned into pBluescript (Stratagene) and
re-isolated as an 800-bp BamHI fragment. This fragment
was then inserted in the BamHI site of the pCLPG vector.
Cell culture and lines
The adenovirus-transformed, human embryo kidney cell
line 293T [23] and the rat glioma cell line C6 (ATCC
CCL-107) were maintained in DMEM (Invitrogen, USA)
supplemented with 10% bovine calf serum (BCS,
HyClone, Logan, UT, USA), 100 μg/ml gentamycin, 50
μg/ml ampicillin, and 2.5 μg/ml fungizone, at 37 °C, in a
humidified atmosphere of 5% CO2. The mouse melanoma
cell line B16F10 (B16, ATCC CRL-6475) was cultured as
above, except using RPMI (Invitrogen, USA).
Virus production
To produce virus-containing supernatant, the appropri-
ate viral vectors were co-transfected in 293T cells as
described [24], except using pCMV-gag-pol and pCMV-
VSVg packaging vectors (kindly provided by Richard
Mulligan, Harvard Medical School, Boston, MA, USA
and Jane Burns, University of California, San Diego, USA,
respectively). The virus-containing supernatant was col-
lected 24 hours post-transfection, centrifuged for 5 min-
utes, 1000 × g, and the supernatant was aliquoted and
stored at -70 °C. Titration was performed either by end-
point dilution determined by G418 resistance or, when
possible, by counting eGFP-positive cells by flow cytome-
try. These protocols have been described previously [25].
Typical titers were in the range of 1 to 5 × 106 colony
forming units (cfu)/ml.
Growth curve
The indicated cell type was plated, 7.5 × 105 cells/6 cm
dish, and transduction was initiated the following day
with equal quantities and concentrations of the indicated
viruses (1 × 106 particles in 1.5 ml) or mock transduced in
the presence of polybrene, 8 μg/ml. The transduction was
allowed to proceed for 8 hours before a second round of
transduction was initiated and allowed to proceed over-
night. A third round of transduction was initiated the fol-
lowing morning and allowed to proceed for 6 hours. At
the end of the transduction, the cells were trypsinized,
counted and replated, 1 × 104 cells of each transduction
were plated in each of the wells in a 12-well dish with
complete medium (DMEM for C6 or RPMI for B16). Two
wells per day, where day 1 represents 24 hours post
replating, were trypsinized and counted manually.
Colony formation assay
The indicated cell type was plated, 2 × 105 cells/well in 6-
well dishes, and transduced the following day with equal
quantities and concentrations of the indicated viruses (4
× 105 particles in 600 μl) or mock transduced in the pres-Merkel et al. BMC Cancer 2010, 10:316
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ence of polybrene, 8 μg/ml. After 4 hours incubation at
37˚C, the virus supernatant was replaced with fresh
medium. The next day, cells were harvested, counted, and
re-plated at 7.5 × 103, 1.0 × 104, 2.5 × 104 and 5.0 × 104
cells/dish in 6 cm dishes. The following day, the medium
was replaced with fresh, complete medium (DMEM for
C6 or RPMI for B16) containing 800-1000 μg/ml of G418
and cells were incubated until mock transduced cells had
died, about 7 days. Then, medium was replaced and colo-
nies allowed to form until clearly visible, usually an addi-
tional 7-14 days. Cells were fixed with 0.5%
paraformaldehyde and stained with crystal violet. For
quantification, the crystal violet was recovered in 10%
acetic acid and the absorbance read at 590 nm using a
spectrophotometer. The positive control, the colonies
resulting from the empty pCLPG vector, was considered
as 100%.
Immunofluorescence detection of p53 and p19Arf
Cells were transduced as per the growth curve assay and
then replated on 13 mm round glass coverslips, 5 × 104
cells/well, in 24 well dishes. Following the final round of
transduction, either fresh medium, medium containing
100 ng/ml doxorubicin or medium containing 10 μM
nutlin-3 was used and the cells incubated for an addi-
tional 24 hours. The cells were fixed with cold methanol,
blocked with bovine serum albumin, then probed with a
polyclonal antibody for p19Arf (AB-1, Cal-Biochem) fol-
lowed by an Alexa-488 labeled anti-rabbit secondary anti-
body. Staining for p53 was performed with a pan-p53
monoclonal antibody (clone G59-12, BD Biosciences) fol-
lowed by Cy3 labeled anti-mouse secondary antibody.
Nuclear staining was performed with Hoechst 33258, 20
μg/ml. Cells were visualized by confocal microscopy at
either 20 × amplification (B16) or 20 × plus 4 × zoom
(C6).
Northern blot
For the Northern blots, 2 6-cm dishes of each cell line
were transduced as per the growth curve assay. The
transduced cells were then treated overnight at 37˚C with
complete medium or medium plus 100 ng/ml of doxoru-
bicin. Total RNA was purified using Trizol reagent (Invit-
rogen Life Technologies, USA) according to the
manufacturer's instructions and samples were analyzed
as described previously [21].
Western blot detection of p19Arf
Cells were transduced and treated with drugs as
described for the p53 activation assays. Protein lysates
were made 24 hours after initiation of drug treatment and
western blot analysis was performed. Briefly, RIPA buffer
(1% NP-40, 0.1% SDS, 0.5% Sodium Deoxycholate in 1 ×
PBS) supplemented with complete mini protease inhibi-
tor cocktail (Roche) was used to lyse cells, the protein
concentration was determined and then 20 μg was sub-
j e c t e d  t o  S D S - P A G E  b e f o r e  t r a n s f e r  t o  H y b o n d  E C L
membrane (GE Lifesciences) and probing with an anti-
p19Arf antibody (Ab-1, CalBiochem), anti-p21 (sc-756,
Santa Cruz Biotechnology) or β-Actin (A5441, Sigma).
Secondary antibodies labeled with horse-radish peroxi-
dase were applied and detected with ECL-Plus reagent
according to the manufacturer's protocol (GE Life-
sciences).
p53 activation measured in a reporter assay
For the reporter assays, cells were transduced with
pCLPG, pCLeGFP or pCLPGeGFP viruses and selected
for G418 resistance, as reported previously [26]. Cells
were replated, 1 × 106 cells/6 cm dish, and transduced (as
described for the growth curve assays) with the indicated
virus. At the end of the transduction, cells were replated
at approximately 50% density in 6-well dishes. The
medium in duplicate wells was changed the next day
(DMEM for C6 or RPMI for B16) or replaced with
medium containing 100 ng/ml doxorubicin or 10 μM
nutlin-3 (N6287, Sigma, USA). The cells were incubated
for 24 hours before harvesting for flow cytometric assess-
ment of eGFP expression and, in parallel, analysis of cell
cycle as revealed by propidium iodide staining as
described previously[26]. The median intensity of eGFP
e x p r e s s i o n  w a s  d e t e r m i n e d  b y  t h e  F A C S  s o f t w a r e  a n d
then normalized considering the positive control
(pCLeGFP) as one.
Cell viability assay
Cells were transduced as described for the growth curve.
For the MTT assay, 96-well dishes were seeded with 1 ×
104 cells from each transduction using complete medium
(DMEM for C6 or RPMI for B16) in quadruplicate wells.
The next day, fresh medium or medium containing the
indicated quantities of drug was applied to the dishes.
Cells were incubated for an additional 48 hours before
determination of cell viability. Plates were incubated with
25 μl of MTT solution (5 mg/ml in 1 × PBS), 37°C during
4 hours. The dish was then removed and the precipitate
solubilized by the addition of 100 μl lysis buffer (20% SDS
in 50% DMF/2% acetic acid, pH adjusted to 4.7) before
analysis using a plate reader at 590 nm.
Animal model
Procedures and conditions for these experiments were
approved by the Scientific and Ethics Committee of the
Intituto do Coração (2833/06/128) and Hospital das Clin-
icas (735/06), University of São Paulo School of Medicine.
B16 cells were transduced ex vivo, as described for the
growth curve assay, with pCLPG or pCLPGp19 virus, in
10 cm dishes. Upon completion of the final round ofMerkel et al. BMC Cancer 2010, 10:316
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transduction, the cells were replated in triplicate 10 cm
dishes and allowed to reach 80% density before medium
was replaced with fresh RPMI containing no drug or
RPMI containing 25 ng/ml doxorubicin or 10 μM nutlin-
3 .  T h e  n e x t  d a y ,  c e l l s  w e r e  h a r v e s t e d ,  c o u n t e d  a n d
injected subcutaneously in the flank, 1 × 106 cells per
C57BL/6 mouse (n = 4), in 100 μl PBS. Tumors were
allowed to develop during 15 days, then all animals were
injected i.p. with 100 mg/kg bromodeoxyuridine, BrdU,
maintained for an additional 4 hours, then sacrificed and
tumors were collected and analyzed. One half of each
tumor was submitted to frozen sectioning while the
remaining half was fixed in paraformaldehyde 4% fol-
lowed by inclusion in paraffin. Histologic sections, 3-5
μm, were prepared and stained with hematoxylin and
eosin (HE). Necrotic area was identified visually in 3 sec-
tions from each tumor and quantified using ImageJ soft-
ware (15-20 fields for each section) and the ratio of
necrotic/non-necrotic tissue was determined.
BrdU staining was performed using paraffin embedded
sections and following the protocol supplied with the
BrdU peroxidase staining kit (Zymed laboratories).
TUNEL staining was performed using frozen sections
and following the protocol supplied with the In situ cell
death detection kit, Fluorescein (Roche Applied Biosci-
ences).
Results
Reliable expression of p19Arf when delivered by the pCLPG 
retrovirus to cell lines harboring wild type p53
W e sough t t o tar get endogenous p53 wt to both drive
vector expression and inhibit tumor proliferation by
including the p19Arf cDNA in the pCLPG retrovirus, a
vector that contains a p53-responsive promoter used to
control expression of the transgene (Figure 1). To con-
firm transgene expression, we first performed immuno-
fluorescence staining of B16 (mouse melanoma, wild-
type p53, p19Arf null) and C6 (rat glioma, wild-type p53,
p19Arf null) cells transduced with pCLPGp19 or, as a
control, with the empty pCLPG retrovirus. For both cell
lines, we readily detected exogenous p19Arf localized in
the nucleolus only in the presence of the pCLPGp19 virus
(Figure  2). The presence of endogenous p53 was also
examined by immunofluorescence staining. The treat-
ment of C6 cells with pCLPGp19 facilitated the detection
of endogenous p53 which was localized in close proxim-
ity to p19Arf. Similar treatment of B16 did not reveal
endogenous p53 (Figure 2).
Northern blots showed that viral expression from the
pCLPG vectors in B16 cells was generally weaker than
that seen for C6 cells, but the presence p19Arf aided viral
expression and viral transcripts were readily detected
(Figure 3). Treatment of the cells with doxorubicin (an
inhibitor of topoisomerase II and DNA damaging agent
well known for its ability to activate p53) did result in
increased viral expression in both cell lines. At least in
this assay, the p19Arf transgene appears to have
enhanced vector expression.
Prior to Western blot analysis, B16 and C6 cells were
subjected to gene transfer with or without exposure to
doxorubicin or nutlin-3 (an inhibitor of mdm2). As seen
in  Figure  4 ,  t r a n s d u c t i o n  o f  e i t h e r  c e l l  l i n e  w i t h
pCLPGp19 yielded readily detectable levels of p19Arf,
but the protein level was not increased upon drug treat-
ment. Induction of p21 (Cdkn1a) expression was accom-
plished by either p19Arf gene transfer or drug treatment.
Though p21 is a known p53 target, we cannot rule out its
activation by p53-independent mechanisms.
In all, these assays indicate that the expression of
p19Arf from the pCLPG vector was reliable in p53 wt-
positive cells.
Figure 1 Schematic representation of the p53-responsive pCLPG retroviral vectors. These vectors contain a p53-responsive element, called PG, 
inserted in the retroviral long terminal repeat. This modification results in p53-dependent transgene expression [21,22]. R U5, native regulatory ele-
ments of the Moloney Murine Leukemia Virus long terminal repeat; SV40, simian virus 40 promoter; NeoR, neomycin phosphotransferase cDNA which 
confers resistance to the antibiotic G418; eGFP, enhanced green fluorescent protein; p19, mouse p19Arf cDNA.Merkel et al. BMC Cancer 2010, 10:316
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Proliferation of B16 cells is not altered by treatment with 
pCLPGp19, yet C6 cells are inhibited
In a growth curve assay, the p53-responsive pCLPG vec-
tors were tested for their ability to inhibit the prolifera-
tion of B16 or C6 cells. Treatment of B16 cells with the
pCLPGp19 vector did not confer a reduction in prolifera-
tion, but was successful for C6 (Figure 5a). Alterations in
growth were not detectable when either B16 or C6 cells
were treated with pCLPGp53 or pCLp53, a retroviral vec-
Figure 2 Exogenous p19Arf detected by immunofluorescence. Cells were transduced and, 24 hours later, fixed with methanol and exposed to a 
polyclonal antibody for p19Arf and a monoclonal antibody for p53 and detection with Alexa-488 anti-rabbit and Cy3 anti-mouse secondary antibod-
ies. Cells were then stained with Hoechst 33258. For B16, we show only the 20 × magnification confocal photomicrographs, no staining of p53 was 
visible at higher magnification. For C6, the appearance of p19Arf at 20 × magnification was comparable to that shown for B16, however endogenous 
p53 staining was observed in C6. We show C6 at 20 × magnification plus 4 × zoom in order to emphasize p53 staining. All photos for either B16 or C6 
were captured using identical settings. Merge refers to the combined images of the green, red and blue channels.
B16 C6
p19Arf Merge p19Arf p53 Merge p53
pCLPG
pCLPGp19
Figure 3 Northern blot analysis reveals that presence of p19Arf aids pCLPG vector expression. B16 (A) or C6 cells (B) were mock transduced or 
transduced with equal quantities of pCLPG, pCLPGeGFP or pCLPGp19 in duplicate dishes. One dish from each duplicate was treated with 100 ng/ml 
of doxorubicin (Dox) and the other was maintained in fresh medium for 24 hours before harvesting total RNA used to perform the Northern blot anal-
yses. Membranes were probed sequentially using the radiolabeled cDNAs of neomycin phosphotransferase (Neo), p19Arf (p19) or, as a control for 
loading, βActin.Merkel et al. BMC Cancer 2010, 10:316
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tor with constitutive expression driven by the native LTR
(data not shown).
Similarly, a colony formation assay showed no effect
when B16 cells were transduced with pCLPGp19 as com-
pared to the control, yet colony formation in C6 cells was
efficiently reduced in the presence of pCLPGp19 (Figure
5B). B16 cells were completely resistant to treatment with
pCLPGp53 or pCLp53 in this assay (data not shown). In
comparison, both pCLPGp53 and pCLp53, inhibited col-
ony formation in C6 cells by about 50% (data not shown).
Since expression from the pCLPGp19 vector was reli-
able in both cell lines, yet each responded differently, we
explored whether the barrier to proper p19Arf function
involved the activation of p53.
Combined pCLPGp19 and drug treatments induce p53 
function in an additive manner
We set up a quantitative assay to measure the impact of
combined gene transfer and drug treatment on p53 activ-
ity. For this, activity of p53 was measured in cells where
pCLPGeGFP had been introduced to serve as a reporter
and selected for G418 resistance. These cells were then
transduced with a second pCLPG vector, subjected to
drug treatments and eGFP reporter activity was quanti-
fied by flow cytometry.
The introduction of pCLPGp19 resulted in weak induc-
tion of p53 activity in B16 cells, an approximate 1.75-fold
increase as compared to the pCLPGeGFP reporter activ-
ity in the absence of either drug or genetic alteration (Fig-
ure 6A). Pharmacologic induction of p53 activity could
be achieved in B16 cells with doxorubicin, with or with-
out pCLPGp19. In contrast, nutlin-3 treatment alone was
not sufficient to stimulate significant p53 activity. Inter-
estingly, p53-dependent reporter activity could be
induced 2.5-fold by the combined treatment with
pCLPGp19 and nutlin-3. This result shows that combin-
ing genetic and pharmacologic treatments had an addi-
tive effect in activating p53 in B16 cells.
In comparison, p53 activity in C6 cells was more effi-
ciently induced by individual pCLPGp19 gene transfer or
nutlin-3 treatments and yielded an additive effect when
combined (Figure 6B).
Cell cycle analysis was performed in parallel with the
experiments described above (Figure  6C and 6D). We
observed that the combined treatment with pCLPGp19
plus drugs resulted in profoundly altered cell cycle pat-
terns. For example, the combined treatment of B16 cells
with pCLPGp19 and nutlin-3 resulted in a marked G1
arrest, whereas individual treatments produced little
change in these cells. Treatment with doxorubicin pro-
duced a G2 arrest, yet the introduction of p19Arf in com-
bination with doxorubicin yielded a G1 arrest. Cell cycle
alterations in C6 cells followed a similar pattern, but with
some subtle differences. In C6, treatment with nutlin-3
caused a pronounced G1 arrest that was slightly
enhanced in the presence of pCLPG19.
We interpret these results as in indication that B16 cells
are more resist to the activation of p53 than C6 when
using either p19Arf gene transfer or nutlin-3 treatment.
However, the combined treatments resulted in more
highly activated p53 and marked cell cycle alterations.
pCLPGp19 gene transfer pre-sensitizes cells to drug 
treatment
To determine whether the functional activation of p53 by
the combination of pCLPGp19 gene transfer plus drug
treatment is associated with a decrease in cell viability, we
used a standard MTT assay. Cells were plated and then
transduced with the pCLPG viruses. The next day, cells
were collected, counted and replated in 96-well dishes.
For these assays, drug treatments were allowed to pro-
ceed for 48 hours before MTT staining of viable cells. B16
Figure 4 Western blot analysis of p19Arf and p21 (Cdkn1a) expression upon gene transfer and drug treatments. B16 (left) and C6 (right) cells 
were mock transduced or transduced with pCLPG or pCLPGp19 followed by treatment with 100 ng/doxorubicin or 10 μM nutlin-3 (lanes labeled D 
or N, respectively) or no drug (-). Exogenous p19Arf, endogenous p21 and β-Actin were revealed using specific primary antibodies followed by sec-
ondary HRP-conjugated antibody/ECL detection.Merkel et al. BMC Cancer 2010, 10:316
http://www.biomedcentral.com/1471-2407/10/316
Page 7 of 14
cells previously transduced with pCLPGp19 were ren-
dered more sensitive to treatment with either doxorubi-
cin or nutlin-3 (Figure 7A). Consistent with the previous
assays, the combined treatment with p19Arf and nutlin-3
reduced the viability of B16 cells.
In C6 cells we observed that treatment with pCLPGp19
alone reduced viability by about 50%, consistent with the
growth curve assays (Figure 7B). Though C6 cells were
quite sensitive to either nutlin-3 or doxorubicin, a subtle
but consistent additional reduction in viability was seen
by combining p19Arf gene transfer with pharmacologic
therapies. So far, our results suggest that re-activating p53
by a combination of p19Arf gene transfer along with
pharmacologic agents may present an interesting option
for tumor cell inhibition, especially in cells that retain
wild-type, but functionally inactive, p53.
Combined p19Arf and nutlin-3 treatment induces death of 
B16 cells in vivo
In an attempt to assess the impact of gene transfer and
drug treatment in an animal model, B16 cells were trans-
duced with pCLPG or pCLPGp19 and treated with doxo-
rubicin or nutlin-3 ex vivo. Cells were then implanted
subcutaneously in C57BL/6 mice and tumors were recov-
ered on day 15. Reduction in tumor size was conferred by
drug treatment, yet gene transfer did not to contribute to
this result (Figure 8). As shown in Figure 9, tissue sec-
tions stained with HE revealed a statistically significant
increase in areas of necrosis when the cells had been
treated with the combination of pCLPGp19 gene transfer
and nutlin-3, but not by either treatment alone (student's
t-test, p = 0.0012).
Tumor cell proliferation was revealed by incorporation
of BrdU prior to sacrifice followed by its immunohis-
Figure 5 B16 cell proliferation is resistant to 19Arf gene transfer. (A) B16 (left) or C6 cells (right) were transduced with equal quantities of pCLPG 
(diamonds), pCLPGeGFP (squares) or pCLPGp19 (triangles) and replated for assessment of growth potential measured by counting cells each 24 hours 
during a 6 day period. Results presented are representative of three independent experiments. (B) B16 (left) or C6 cells (right) were transduced with 
equal quantities of pCLPG , pCLPGeGFP or pCLPGp19 and replated for the colony formation assay. The number of G418-resistant colonies counted in 
the pCLPG condition was considered as 1 and the colonies formed in the other conditions were normalized to this value. The results shown are the 
mean and standard deviation of three experiments.Merkel et al. BMC Cancer 2010, 10:316
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tochemical detection in the histologic sections. As shown
in Figure 10, BrdU staining was greatly reduced when the
cells had been treated by combined pCLPGp19 gene
transfer plus doxorubicin or nutlin-3 treatments, yet
application of these treatments individually did not
appreciably alter BrdU staining. TUNEL staining was
performed, but no difference was observed among the
experimental conditions (data not shown).
Discussion
Both here and in previous studies [22,27], we saw that
B16 and C6 are particularly resistant to p53 treatment.
Since these cells harbor endogenous p53wt, they must
possess a mechanism for maintaining p53 in an inactive
state, such as the loss of p19Arf or over-expression of
mdm2. Treatment approaches in this case include the re-
activation of p53 by gene transfer or drug treatment. For
Figure 6 Induction of endogenous p53 activity by combined gene and drug therapy. Cells were transduced with pCLeGFP as a control or the 
p53-responsive retroviral reporter pCLPGeGFP and selected for G418 resistance. For the assays, the B16 (A) or C6 (B) reporter cells were either mock 
transduced or transduced with pCLPGp19, replated in 6-well dishes and then treated with drug as indicated. The following day, cells were harvested 
for flow cytometric analysis of eGFP expression. The mean eGFP intensity was determined by the FACS software and the value for pCLeGFP used for 
normalization. Shown is the average and standard deviation of duplicate samples performed in three independent experiments. Cell cycle analysis (C 
and D) was performed in parallel with the assays shown in A and B.Merkel et al. BMC Cancer 2010, 10:316
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example, introduction of p19Arf can activate p53 and
complement its function. We set out to show that the
p53-responsive pCLPG retroviral vector could be used to
introduce p19Arf, uniting transgene function and control
over its expression. That is to say, exogenous p19Arf
should activate endogenous p53 and, in turn, reinforce
expression from the pCLPG vector, resulting in even
higher levels of exogenous p19Arf. We had hoped to
observe that p19Arf gene transfer would be sufficient to
inhibit proliferation, as was the case with C6 cells. In con-
trast, B16 cells were more resistant to the effects of
p19Arf and required additional drug treatment in order
to reduce viability.
Using a p53-responsive vector for the delivery of
p19Arf to cancer cell lines that harbor p53wt established
interplay between the vector, transgene and cellular com-
ponents of the p53 pathway. However, the introduction of
the pCLPGp19 vector resulted in distinct responses
between the B16 and C6 cell lines. B16 cells were rela-
tively resistant to either genetic or nutlin-3 treatments
when applied individually, but their combination led to
the activation of endogenous p53 and reduction in cell
viability both in culture and in an animal model. In con-
trast, C6 cells were permissive to the activities of either
p19Arf or nutlin-3 treatments as shown by the functional
activation of endogenous p53.
The treatment of B16 cells with pCLPGp19 alone did
not result in the reduction of proliferation, yet viral
expression was reliable. Exogenous p19Arf was readily
detected and was localized to the nucleolus. Since North-
ern and Western blots also confirmed viral expression, we
proposed that p53 was not efficiently activated in B16
cells and that this may have been responsible for the con-
tinued proliferation of these cells. Holding p19Arf in the
nucleolus due to its interaction with nucleophosmin is
thought to prevent interaction of Arf with mdm2, which
occurs in the nucleoplasm [28], though this is reversed
when DNA damage is induced [29]. We observed that
treatment with doxorubicin did not noticeably alter the
localization of p19Arf (data not shown), though we used a
Figure 7 pCLPGp19 gene transfer presensitizes cells to subsequent drug treatment as measured by an MTT cell viability assay. B16 (A) or 
C6 cells (B) were transduced with equal quantities of pCLPG (diamonds), pCLPGeGFP (squares) or pCLPGp19 (triangles), replated in 96-well plates and 
quadruplicate samples were treated with drug as indicated for 48 hours before cell viability was assessed by MTT staining. The MTT absorbance ob-
served in cells transduced with pCLPG, but without drug treatment, was used to normalize the values. Results represent the average and standard 
deviation of three independent experiments.Merkel et al. BMC Cancer 2010, 10:316
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relatively low drug dose. However, the treatment with the
DNA-damaging agent doxorubicin was sufficient to acti-
vate p53 in both cell lines.
Gene transfer studies have shown that introduction of
exogenous p14ARF could activate endogenous p53 wt
more efficiently when both p14ARF and p53 were intro-
duced simultaneously by adenoviral vectors [12,13]. Simi-
larly , we observed that introduction of p19Arf was not
sufficient to activate p53 in B16 cells. Interestingly, B16
cells were pre-sensitized to drug treatment by prior expo-
sure to pCLPGp19. p19Arf gene transfer followed by
treatment with nutlin-3 lead to markedly increased p53
activity, cell cycle alteration and reduced viability.
Though C6 cells were more permissive to p19Arf or nut-
lin-3 treatments, their combination was beneficial in
increasing the response to p53 stimulation. We propose
that p53-responsive vectors may prove beneficial in func-
tional and therapeutic studies of gene transfer in tumor
models that present p53 wt, especially when combined
with drug treatment.
Multiple pathways are involved in regulating p53 activ-
ity. Since C6 was sensitive to nutlin-3 treatment, we
expect that p53 activity was squelched primarily through
mdm2. In contrast, B16 cells probably possess additional
mechanisms of abrogating p53 activity since these cells
were quite resistant to nutlin-3. Reports in the literature
point out that mdmx (mdm4) can render cells resistant to
nutlin-3 treatment [17,18] and the interaction of p19Arf
with mdmx is thought to inhibit mdmx activity [19,20].
Western blot analysis of mdmx in presence or absence of
pCLPGp19, doxorubicin or nutlin-3 did not reveal any
alteration in protein level or mobility (data not shown).
Therefore, the mechanism for the resistance of B16 cells
to nutlin-3 as well as the reason for p53 re-activation by
the combination of p19Arf and nutlin-3 remains to be
determined.
The treatment with either p19Arf or nutlin-3 should
result in the neutralization of mdm2. However, each acts
through a distinct mechanism. Nutlin-3 occupies the site
on mdm2 where p53 would otherwise be bound. p19Arf,
on the other hand, blocks the E3 ubiquitin ligase activity
of mdm2. In this case, the influence of p19Arf may reach
beyond p53 and include other factors with which mdm2
interacts, such as Hif1α [30] and PML [31].
Since treatment with pCLPGp19 was quite effective in
C6 cells, we conclude that it is possible to use endogenous
p53 to drive viral expression of p19Arf and bring about an
increase in p53 activation and the concomitant reduction
in cell proliferation. The resistance of B16 to p53 activa-
tion upon pCLPGp19 or nutlin-3 treatment may be par-
ticular for this cell line. However, B16 cells are widely
studied as a model for melanoma and are particularly
Figure 8 Volume of B16 tumors. B16 cells were transduced with either pCLPG (black bars) or pCLPGp19 (gray bars) and then treated with 25 ng/ml 
doxorubicin (Dox) or 10 μM nutlin-3, as indicated, before subcutaneous injection of 1 × 106 cells in C57BL/6 mice (n = 4/condition). After 15 days, the 
animals were sacrificed, tumors removed and measured. Tumor volume was determined using the formula V = π/6 × D1 × D2 × D3 (where D is the 
dimension in mm). Presented is the mean and standard deviation of the observed tumor volumes.Merkel et al. BMC Cancer 2010, 10:316
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Figure 9 Animal model of B16 tumor formation reveals increased necrosis when cells were treated with both pCLPGp19 and nutlin-3. B16 
cells were transduced ex vivo with pCLPG or pCLPGp19 followed by treatment with 25 ng/ml doxorubicin (dox) or 10 μM nutlin-3 (Nutlin) before sub-
cutaneous implantation of 1 × 106 cells in C57BL/6 mice (n = 4/condition). After 15 days, the animals were sacrificed and tumors were analyzed histo-
logically upon staining with HE. The ratio between necrotic and non-necrotic areas in photomicrographs of the HE sections was determined using 
ImageJ software and is presented as the mean and standard deviation of 15 to 20 fields from each of 3 sections from each tumor (*, student's t-test, 
p = 0.0012).Merkel et al. BMC Cancer 2010, 10:316
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interesting since they can be studied in a syngeneic,
immunocompetent animal model.
Analysis of tumor formation after ex vivo gene transfer
and/or drug treatment revealed findings consistent with
those described for the in vitro assays. Here too, inhibi-
tion of B16 proliferation and viability was revealed upon
combined p19Arf gene transfer and nutlin-3 treatments.
At the end of the 15 day observation period, tumor size
was not a reliable indicator of the impact of treatment.
However, a significant increase in necrotic tissue was
revealed in tumors derived from B16 cells treated with
both pCLPGp19 and nutlin-3. We did not find increased
TUNEL staining upon gene transfer or drug treatments,
possibly due to the kinetics of the treatment or due to the
Figure 10 Decreased proliferation, as revealed by BrdU incorporation, was associated with double treatment conditions. Prior to sacrifice, 
animals were injected i.p. with a solution of BrdU. Paraffin embedded sections of tumors were probed with an anti-BrdU antibody conjugated to al-
kaline phosphatase and revealed through a peroxidase reaction.Merkel et al. BMC Cancer 2010, 10:316
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advanced stage of necrosis. A concomitant reduction in
proliferation, as revealed by BrdU staining, was also seen
in tumors arising from the doubly treated cells.
Conclusions
In this study, we have explored the functional activation
of endogenous p53 when p19Arf was introduced by a
p53-responsive vector. In the absence of drug treatment,
we observed reliable expression of exogenous p19Arf
driven by endogenous p53. C6 cells were quite sensitive
to either p19Arf gene transfer or nutlin-3 treatment alone
and when combined these treatments yielded in additive
effect. B16 cells were generally quite resistant to p19Arf
or nutlin-3 treatments, though the combination of these
resulted in markedly increased p53 activity as well as
reduced viability. To the best of our knowledge, this work
represents the first attempt to unite p19Arf gene transfer
and nutlin-3 treatments. Here we have shown that com-
bined treatments activated p53 and reduced the viability
of B16 cells.
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